For the third time this year, Novartis has been rebuked by a U.K. trade group for misleading promotional efforts for its biggest-selling drug and, in the process, bringing discredit on the entire pharmaceutical industry.
In the latest instance, the company was cited for making unsubstantiated and spurious claims in a podcast that was promoting the Entresto heart failure medication to nurses. The episode downplayed a key safety issue — the importance of kidney function — and inappropriately suggested the drug was the best treatment option, among other problematic matters.
As a result, Novartis committed several violations of a voluntary code maintained by the Prescription Medicines Code of Practice Authority, which is a self-regulatory body overseen by the Association of the British Pharmaceutical Industry. The PMCPA was created 30 years ago to bolster the industry’s reputation and has become a receptacle for complaints, often by physicians and company employees.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect